Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

November 30, 2014

Conditions
Plaque Psoriasis
Interventions
DRUG

MT-1303-Low

DRUG

MT-1303-Middle

DRUG

MT-1303-High

DRUG

Placebo

Trial Locations (52)

Unknown

Research Site, Dupnitsa

Research Site, Pleven

Research Site, Sofia

Research Site, Tallinn

Research Site, Tartu

Research Site, Bavaria

Research Site, Cologne

Research Site, Düsseldorf

Research Site, Essen

Research Site, Gera

Research Site, Hamburg

Research Site, Hanau

Research Site, Hessen

Research Site, Kiel

Research Site, Lübeck

Research Site, Mainz

Research Site, Debrecen

Research Site, NyÃ-regyháza

Research Site, Orosháza

Research Site, Szeged

Research Site, Veszprém

Research Site, Jelgava

Research Site, Madona

Research Site, Riga

Research Site, Ventspils

Research Site, Bialystok

Research Site, Bydgoszcz

Research Site, Gdansk

Research Site, Katowice

Research Site, Lodzkie

Research Site, Malopolska

Research Site, Olsztyn

Research Site, Środa Wielkopolska

Research Site, Warsaw

Research Site, Woj. Wielkopolskie

Research Site, Wroclaw

Research Site, Chelyabinsk

Research Site, Moscow

Research Site, Saint Petersburg

Research Site, Saratovskaya

Research Site, Yaroslavl

Research Site, Dniepropetrovsk

Research Site, Dnipro

Research Site, Donetskaya

Research Site, Kyiv

Research Site, Luhansk

Research Site, Lviv

Research Site, Odesa

Research Site, Simferopol

Research Site, Ternopil

Research Site, Uzhhorod

Research Site, Zaporizhzhya

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY